WFH Advisory: availability of desmopressin pending
re-start of intranasal desmopressin manufacture
Register now!
The CHS is hosting a live educational videoconference on Monday, November 2, from 7:00 to 8:30 p.m. ET,
aimed at improving understanding of FVIII/ FIX inhibitors and treatment options, with a special focus on emicizumab.
Click on the image or below to access the charts featuring
the coagulation products for all bleeding disorders.
Recombinant factor VIII
Factor VIII & von Willebrand factor (plasma-derived)
Recombinant factor IX
Factor IX (plasma-derived)
Recombinant von Willebrand factor
Products for patients with inhibitors
Products to treat rare factor deficiencies
Click on the image or below to access the charts featuring the products in the pipeline.
CLICK HERE to access the
Submission to the Canadian Agency for Drugs and Technologies in Health (CADTH)
by the CHS on Hemlibra
Click here to access the submission to the Institut national d'excellence en santé et en services sociaux in Quebec (in French)
CLICK HERE to access the 2020 Canadian Integrated and Comprehensive Care Standards for Inherited Bleeding Disorders
Click here to access the self-assessment checklist
Patient perspectives and economic consequences of frequent tenders for clotting factors
A team of Canadian hemophilia researchers are doing this study to learn more about the views, experiences, and economic impact related to frequent tender changes, among Canadian patients with hemophilia, or parents/ caregivers of someone with hemophilia.
We do not know the impact of mandated product changes on Canadian patients and families, such as worries about the safety and effectiveness of the new product, extra clinic visits and bloodwork, extra costs from visits, and emotional distress from frequent treatment changes.
The survey is anonymous. It will take around 15-20 minutes of your time to complete.
